Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Wolf; Michael
Address:
Darmstadt, DE
No. of patents:
38
Patents:












Patent Number Title Of Patent Date Issued
8119795 Triazole derivatives II February 21, 2012
Novel triazole derivatives of the formula (I) in which R.sup.1-R.sup.6 and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 p
7989625 Thienopyridines August 2, 2011
The invention relates to novel thienopyridine derivatives of formula (I), wherein R1, R2, R3, R4 and Y have the meaning cited in claim 1, are HSP90-inhibitors and can be used for producing a medicament for treating illnesses, wherein the inhibition, regulation and/or modulation of HSP90
7977343 Adenine derivatives July 12, 2011
Novel adenine derivatives of the formula (I), in which R.sup.1, R.sup.2, R.sup.3, X and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulati
7947696 2-amino-4-phenylquinazoline derivatives and the use thereof as HSP90 modulators May 24, 2011
Novel phenylquinazoline derivatives of the formula (I), in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regu
7943637 Thienopyridine derivatives and the use thereof as HSP90 modulators May 17, 2011
Novel thienopyridine derivatives of the formula (I), in which R.sup.1, R.sup.2, R.sup.3 and Y have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modu
7932401 1,5-diphenylpyrazoles April 26, 2011
Novel 1,5 diphenylpyrazole derivatives of the formula (I), in which R.sup.1-R.sup.6 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of
7906657 1,5-diphenylpyrazoles II as HSP90 inhibitors March 15, 2011
Novel 1,5-diphenylpyrazole derivatives of the formula (I) in which R.sup.1-R.sup.6 have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of H
7790723 Thiazole derivatives as phosphodiesterase IV inhibitors September 7, 2010
Thiazole derivatives of the formula I ##STR00001## in which R.sup.1, R.sup.2, R.sup.3, V, W, X and B are as defined in claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, mult
7652756 Method and apparatus for centering an ophthalmic lens January 26, 2010
An ophthalmic lens , e.g. a contact lens, is centered in a concave trough (10) of an inspection cell (1) which is filled with liquid (W). The inspection cell (10) has a channel (11) which is in communication with the concave trough (10). Centering of the ophthalmic lens is achieved by
7563790 Pyridazine derivatives July 21, 2009
Pyridazine derivatives of the formula (I) act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune
7544684 Hydrazono-malonitriles June 9, 2009
Hydrazono-malonitrile derivatives of the formula (I) in which R.sup.1, R.sup.2, R.sup.3, R.sup.3' and R.sup.4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid
7498334 Pyrrolopyrimidines as phosphodiesterase VII inhibitors March 3, 2009
Pyrrolopyrimidine derivatives of the formula I ##STR00001## in which R.sup.3, R.sup.4, R.sup.5, R.sup.6 and X are as defined in claim 1, act as phosphodiesterase VII inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arth
7491742 Imidazole derivatives as phosphodiesterase VII inhibitors February 17, 2009
Imidazole derivatives of the formula I ##STR00001## in which R.sup.1 is H, A, benzyl, indan-5-yl, 1,2,3,4-tetrahydronaphthalen-5-yl, dibenzothien-2-yl, or phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, A-CO--NH, benzyloxy, alkoxy, COOH or COOA, R.sup.2 is H
7485639 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1,2,4)triazin-5-one derivatives having a PDE-IV inh February 3, 2009
Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R.sup.1, R.sup.2, A and R.sup.5 are as defined in Claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of allergic diseases, asthma, chronic b
7470687 Aryl oximes December 30, 2008
Aryl oxime derivatives of the formula (I), in which R.sup.1, R.sup.2, R.sup.3, X and B are as defined in Claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis
7367140 Method of drying molds and apparatus for supplying drying air May 6, 2008
In a method of drying molds or mold parts for the manufacture of optical lenses, in particular ophthalmic lenses and especially contact lenses, the mold or mold part to be dried is exposed to drying air. For this purpose, humid pressurized air (T) is used to which the mold or mold part
7312328 Benzoylpyridazines December 25, 2007
This invention relates to compounds of the formula (I) in which R.sup.1, R.sup.2, R.sup.3, X and Q are as defined above and their use as PDE IV inhibitors.
7141572 Hydrazono-malonitriles November 28, 2006
Hydrazono-malonitrile derivatives of the formula (I) in which R.sup.1, R.sup.2, R.sup.3, R.sup.3' and R.sup.4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid
7135471 Aryl oximes November 14, 2006
Aryl oxime derivatives of the formula (I), in which R.sup.1, R.sup.2, R.sup.3, X and B are as defined in claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis
7129241 Pyridazine derivatives October 31, 2006
Pyridazine derivatives of the formula (I) act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmu
6884800 Imidazole compounds used as phosphodiesterase VII inhibitors April 26, 2005
Imidazole compounds of the formula I ##STR1##in which R.sup.1 and R.sup.2, independently of one another, each denote A.sup.1, OA.sup.1, SA.sup.1 or Hal, A.sup.1 denotes H, A, alkenyl, cycloalkyl or alkylenecycloalkyl, A denotes alkyl having 1-10 carbon atoms, Hal denotes F, Cl, B
6786249 Device for sterilizing packaging using hydrogen peroxide September 7, 2004
Described is an apparatus for simultaneously sterilizing a large number of packs (1) by means of a gas mixture containing hydrogen peroxide and a carrier gas. The apparatus comprises: supply lines (4) for the carrier gas and for hydrogen peroxide (5), a device (21) for evaporating hydrog
6737436 Pyrrole derivatives as phosphodiesterase VII inhibitors May 18, 2004
Compounds of the formula I ##STR1##in which R.sup.1 and R.sup.2, independently of one another, each denote H, A, OA, SA or HaI, R.sup.3 denotes H or A, R.sup.4 denotes A or NH.sub.2, R.sup.5 denotes H, NH.sub.2, NHA or NA.sub.2, A denotes alkyl having 1 to 10 carbon atoms, alk
6696446 Benzoylpyridazines, their preparation and use February 24, 2004
Benzoyl derivatives of formula (I) ##STR1##and their physiologically acceptable salts and solvates, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 have the meanings indicated, inhibit phosphodiesterase IV and can be used for the treatment of allergic diseases, as
6613778 Imidazopyridine derivatives as phosphodiesterase VII inhibitors September 2, 2003
Compounds of the formula I ##STR1##in which R.sup.1 denotes CONR.sup.4 R.sup.5, R.sup.2 denotes H or A, R.sup.4 and R.sup.5, independently of one another, each denote H or A.sup.1, R.sup.3 denotes Hal, Hal denotes F, Cl, Br or I, A denotes alkyl having 1-4 carbon atoms,
6531498 Isoxazole derivatives to be used as phosphodiesterase VII inhibitors March 11, 2003
The invention relates to compounds of formula I and to their physiologically acceptable salts and solvates which act as phosphodiesterse VII inhibitors and are thus useful for the treatment of allergic disorders, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin
6531473 Method of treatment using arylalkylpyridazinones March 11, 2003
Aralkylpyridazinone derivatives of the formula I ##STR1##and their physiologically acceptable saltsin which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and Q have the meanings indicated in claim 1, show inhibition of phosphodiesterase IV and can be employed for the treatment of inflam
6479494 Arylalkanoyl pyridazines November 12, 2002
Arylalkanoylpyridazine derivatives of the formula I ##STR1##and the physiologically acceptable salts thereof in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q and B have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteopo
6417188 Arylalkanoylpyridazines July 9, 2002
Arylalkanoylpyridazine derivatives of the formula I ##STR1##and their physiologically acceptable salts and solvates,in whichR.sup.1, R.sup.2, Q and B have the meanings indicated in Claim 1, show an inhibition of phosphodiesterase IV and can be employed for the treatment of asthma, chroni
6399611 Arylalkylpyridazinones June 4, 2002
Aralkylpyridazinone derivatives of the formula I ##STR1##and their physiologically acceptable salts in whichR.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and Q have the meanings indicated in claim 1, show inhibition of phosphodiesterase IV and can be employed for the treatment of inflammat
6376493 Benzoylpyridazines April 23, 2002
A group of compounds of, the preparation of, and the methods of use of benzoylpyridazine derivatives and the physiologically acceptable salts and solvates thereof, which have valuable pharmacological properties while well tolerated. They selectively inhibit phosphodiesterase IV with an
6107295 Arylalkanoyl pyridazines August 22, 2000
Arylalkanoylpyridazine derivatives of the formula I ##STR1## and the physiologically acceptable salts thereof in whichR.sup.1, R.sup.2, R.sup.3, R.sup.4, Q and B have the meanings given in claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteopo
6025354 Arylalkyl-thiadiazinones February 15, 2000
Arylalkyl-thiadiazinone derivatives of the formula I ##STR1## and physiologically unobjectionable salts thereof in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and Q have the meanings given in claim 1, exhibit phosphodiesterase IV inhibition and can be used for the therapy o
5859008 Arylalkyl diazinones January 12, 1999
Arylalkyl diazinone derivatives of the formula I ##STR1## and their physiologically acceptable salts, in whichR.sup.1, R.sup.2, R.sup.3, R.sup.4, B, Q and X have the meanings indicated in claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of inflam
5747489 Arylalkyl-thiadiazinones May 5, 1998
Arylalkyl-thiadiazinone derivatives of the formula I ##STR1## and physiologically unobjectionable salts thereof in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and Q have the meanings given in claim 1, exhibit phosphodiesterase IV inhibition and can be used for the therapy o
5508390 Diterpenes having immunomodulatory action April 16, 1996
Diterpenes of the formula I ##STR1## in which R.sup.1 is --CH.sub.2 --C(CH.sub.3).dbd.CH--R.sup.3 or --CH.sub.2 --CH(CH.sub.3)--CH.sub.2 --R.sup.3,R.sup.3 is --CH.sub.2 OH, --CHO, --COOH or --COOR.sup.4,R.sup.4 is alkyl having 1 to 5 C atoms,A is ##STR2## and R.sup.2 is H, pentos
5434149 Thiadiazinones July 18, 1995
The present invention relates to thiadiazinones of the formula I ##STR1## having a phosphodiesterase-inhibiting action and which are suitable for combating cardiovascular and asthmatic disorders.
5276027 Thiadiazinones January 4, 1994
Compounds of formula I ##STR1## in which R.sup.1 and R.sup.2 are each independently of one another H or A,R.sup.3 is H, OA or O--C.sub.m H.sub.2m+1-n X.sub.n,R.sup.4 is --O--C.sub.m H.sub.2m+1-n X.sub.n,X is F or Cl,A is alkyl having 1-6 C atoms,m is 1, 2, 3, 4, 5 or 6 andn is 1, 2, 3, 4, 5,










 
 
  Recently Added Patents
Cardiac chamber volume computation from contours and base plane in cardiac MR Cine images
System, method, and software for researching, analyzing and comparing expert witnesses
Polypeptide microparticles
Process for making diethyl ether from acetic acid
Nucleic acid sequences encoding strictosidine synthase proteins
Stool
Machine tool with an electrical generator for passive power generation
  Randomly Featured Patents
Computer front bezel
Method of calling a mobile station in a mobile telephone system
Method and apparatus for converting direct current to alternating current
End cap for fluorescent lamp
Exercise bar with attachment points for weighted plates
Fuel injection nozzle assembly
Air conditioner
Sheath for use with an ultrasound element
Aquatic and pets container
Fiber reinforcing composites comprising portland cement having embedded therein precombined absorbent and reinforcing fibers